Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alvimedica
Catalca, Istanbul, Turkey6sense.com ↗
- Ownership
- Private
- Employees
- ~187
- Development stage
- Commercial
01
Overview
The company’s drug-eluting stents such as Cre8 EVO have demonstrated superior outcomes to competitors in randomized controlled trials. For example, the SUGAR RCT showed Cre8 EVO DES had a lower target lesion failure rate at one year compared to Onyx DES. Earlier clinical and preclinical studies of Coracto indicated favorable endothelial coverage compared to other leading drug-eluting stents.
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceDrug-eluting stentBalloon catheterBiodegradable stent
- Industry
- Implantable Medical Devices
02
Partnerships
Merger with CID S.p.A.
Beyond the preview
Go deeper on Alvimedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alvimedica.